http://orcid.org/0000-0001-9471-9099
Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O’Neill, Bryan T. Hennessy & Sinead Toomey. (2023) Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer. Cancer Biology & Therapy 24:1.
Read now
Read now
Joshua Blume, Luisa Claus, Tamara Isermann, Antje Dickmanns, Lena-Christin Conradi, Ramona Schulz-Heddergott & Matthias Dobbelstein. (2023) CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan. Cell Cycle 22:13, pages 1563-1582.
Read now
Read now
ZhaoHui Xu, Hui Qu, YanYing Ren, ZeZhong Gong, Hyok Ju Ri & Xin Chen. (2021) An Update on the Potential Roles of E2F Family Members in Colorectal Cancer. Cancer Management and Research 13, pages 5509-5521.
Read now
Read now
Mingliang Zhang, Weigang Dai, Zhanyu Li, Liang Tang, Jianhui Chen & Chuangqi Chen. (2021) HSPA4 Knockdown Retarded Progression and Development of Colorectal Cancer. Cancer Management and Research 13, pages 4679-4690.
Read now
Read now
Weixuan Sun, Wenting Nie, Zhaoyi Wang, Haolong Zhang, Yezhou Li & Xuedong Fang. (2020) Lnc HAGLR Promotes Colon Cancer Progression Through Sponging miR‐185‐5p and Activating CDK4 and CDK6 in vitro and in vivo. OncoTargets and Therapy 13, pages 5913-5925.
Read now
Read now
Qin Jin, Gang Liu, Luri Bao, Yuzhen Ma, Huidong Qi, Zhizhong Yun, Yanfeng Dai & Shu Zhang. (2018) High Spy1 expression predicts poor prognosis in colorectal cancer. Cancer Management and Research 10, pages 2757-2765.
Read now
Read now
Noel A. Warfel. (2017) Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance. Cell Cycle 16:13, pages 1241-1242.
Read now
Read now
Articles from other publishers (27)
Maria Mortoglou, Francesc Miralles, Rhys Richard Mould, Dipankar Sengupta & Pinar Uysal-Onganer. (2023) Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21. European Journal of Cell Biology 102:2, pages 151318.
Crossref
Crossref
Jingshan Tong, Xiao Tan, Suisui Hao, Kaylee Ermine, Xinyan Lu, Zhaojin Liu, Anupma Jha, Jian Yu & Lin Zhang. (2023) Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction. Oncogene 42:12, pages 869-880.
Crossref
Crossref
Zhichao Xue, Jiaming Zeng, Xinchi Yin, Yongshu Li, Bo Meng, Yang Zhao, Xiang Fang, Xiaoyun Gong & Xinhua Dai. (2023) Investigation on acquired palbociclib resistance by LC-MS based multi-omics analysis. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Sonal M Manohar. (2022) Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future. Future Medicinal Chemistry 14:14, pages 1087-1105.
Crossref
Crossref
Qi Jia, Li Tao, Yinyin Zhou, Li Song, Zhonghong Wei, Tao Lu, James R. Woodgett & Yin Lu. (2022) Novel GSK-3 kinase inhibitor Pym-5 induces GSK-3β rather than GSK-3α-dependent melanogenesis in murine melanoma cells. Journal of Dermatological Science 106:3, pages 170-180.
Crossref
Crossref
Jingshan TongXiao TanXiangping Song, Man GaoDenise Risnik, Suisui HaoKaylee Ermine, Peng WangHua LiYi HuangJian Yu & Lin Zhang. (2022) CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. Cancer Research 82:7, pages 1340-1352.
Crossref
Crossref
Tobias Ettl, Daniela Schulz & Richard Bauer. (2022) The Renaissance of Cyclin Dependent Kinase Inhibitors. Cancers 14:2, pages 293.
Crossref
Crossref
Fei Wang, Yulian Ding, Xiujuan Lei, Bo Liao & Fang-Xiang Wu. (2021) Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine. IEEE Journal of Biomedical and Health Informatics 25:11, pages 4079-4088.
Crossref
Crossref
Hengtai Bi, Juan Shang, Xiao Zou, Jing Xu & Yumei Han. (2021) Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway. Oncology Letters 22:2.
Crossref
Crossref
Anna Richter, Nina Schoenwaelder, Sina Sender, Christian Junghanss & Claudia Maletzki. (2021) Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. Cancers 13:10, pages 2497.
Crossref
Crossref
Yong-Hwi Kang, Jin-Seok Lee, Nam-Hun Lee, Seung-Hyung Kim, Chang-Seob Seo & Chang-Gue Son. (2021) Coptidis Rhizoma Extract Reverses 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells via Modulation of Thymidylate Synthase. Molecules 26:7, pages 1856.
Crossref
Crossref
Bortecine Sevgin, Merve Coban, Özge Rencuzogullari, Ajda Coker-Gurkan, Pinar Obakan-Yerlikaya, Pinar Uysal Onganer & Elif Arisan. (2021) AMPK Is the Crucial Target for the CDK4/6 Inhibitors Mediated Therapeutic Responses in PANC-1 and MIA PaCa-2 Pancreatic Cancer Cell Lines. Stresses 1:1, pages 48-68.
Crossref
Crossref
Jason A. Somarelli, Roham Salman Roghani, Ali Sanjari Moghaddam, Beatrice C. Thomas, Gabrielle Rupprecht, Kathryn E. Ware, Erdem Altunel, John B. Mantyh, So Young Kim, Shannon J. McCall, Xiling Shen, Christopher R. Mantyh & David S. Hsu. (2020) A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Molecular Cancer Therapeutics 19:12, pages 2516-2527.
Crossref
Crossref
Patrick J. Roberts, Vishnu Kumarasamy, Agnieszka K. Witkiewicz & Erik S. Knudsen. (2020) Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Molecular Cancer Therapeutics 19:8, pages 1575-1588.
Crossref
Crossref
Mara Bonelli, Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Silvia La Monica, Daniele Cretella, Roberta Alfieri, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti & Pier Giorgio Petronini. (2020) Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. International Journal of Molecular Sciences 21:14, pages 5165.
Crossref
Crossref
Lu Yu, Feng Ye, Yi-Yi Li, Yi-Zhi Zhan, Yang Liu, Hong-Mei Yan, Yuan Fang, Yu-Wen Xie, Feng-Jiao Zhang, Long-Hua Chen, Yi Ding & Ke-Li Chen. (2020) Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis. Carcinogenesis 41:5, pages 678-688.
Crossref
Crossref
Benedito A. Carneiro & Wafik S. El-Deiry. (2020) Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology 17:7, pages 395-417.
Crossref
Crossref
Thomas T. DeLeon, Daniel R. Almquist, Benjamin R. Kipp, Blake T. Langlais, Aaron Mangold, Jennifer L. Winters, Heidi E. Kosiorek, Richard W. Joseph, Roxana S. Dronca, Matthew S. Block, Robert R. McWilliams, Lisa A. Kottschade, Kandelaria M. Rumilla, Jesse S. Voss, Mahesh Seetharam, Aleksandar Sekulic, Svetomir N. Markovic & Alan H. Bryce. (2020) Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLOS ONE 15:3, pages e0230306.
Crossref
Crossref
Ozge Rencuzogulları, Pınar Obakan Yerlikaya, Ajda Çoker Gürkan, Elif Damla Arısan & Dilek Telci. (2019) Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial‐mesenchymal transition in Panc‐1 and MiaPaCa‐2 pancreatic cancer cells. Journal of Cellular Biochemistry 121:1, pages 508-523.
Crossref
Crossref
Phillip Wright, Janet Kelsall, Guy Healing & Julie Sanderson. (2019) Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity. Archives of Toxicology 93:3, pages 659-671.
Crossref
Crossref
Jun Zhang, YuanYuan Pei, Wen Yang, WenXiu Yang, BoXin Chen, Xing Zhao & Shiqi Long. (2019) Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals. Molecular Carcinogenesis 58:3, pages 334-343.
Crossref
Crossref
Mary-Ann Bjornsti & Scott H. Kaufmann. (2019) Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Research 8, pages 1704.
Crossref
Crossref
Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli & Pier Giorgio Petronini. (2018) The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
João MA Delou, Karina L Hajdu & Helena L Borges. (2018) Could combinations of new and old drugs enhance tumor cell death?. Future Oncology 14:23, pages 2319-2322.
Crossref
Crossref
Chao-Yuan Huang, Feng-Shu Hsieh, Cheng-Yi Wang, Li-Ju Chen, Shih-Shin Chang, Ming-Hsien Tsai, Man-Hsin Hung, Chiung-Wen Kuo, Chi-Ting Shih, Tzu-I Chao & Kuen-Feng Chen. (2018) Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage response. European Journal of Cancer 102, pages 10-22.
Crossref
Crossref
Thomas T DeLeon, Daniel H Ahn, James M Bogenberger, Panos Z Anastasiadis, Mansi Arora, Ramesh K Ramanathan, Bashar A Aqel, George Vasmatzis, Mark J Truty, Rahmi Oklu, Tanios S Bekaii-Saab & Mitesh J Borad. (2018) Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncology 14:6, pages 553-566.
Crossref
Crossref
Amriti R. Lulla, Michael J. Slifker, Yan Zhou, Avital Lev, Margret B. Einarson, David T. Dicker & Wafik S. El-Deiry. (2017) miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Research 77:24, pages 6902-6913.
Crossref
Crossref